David D. Waters

Active 1975–2026

125
Papers
39,487
Citations
95
h-index
124
i10-index

Citations

Citations per year for David D. Waters1976: 1 citations1979: 4 citations1980: 21 citations1981: 20 citations1982: 21 citations1983: 39 citations1984: 33 citations1985: 32 citations1986: 25 citations1987: 28 citations1988: 22 citations1989: 50 citations1990: 34 citations1991: 39 citations1992: 41 citations1993: 46 citations1994: 54 citations1995: 89 citations1996: 97 citations1997: 82 citations1998: 106 citations1999: 107 citations2000: 118 citations2001: 118 citations2002: 151 citations2003: 203 citations2004: 222 citations2005: 203 citations2006: 245 citations2007: 272 citations2008: 302 citations2009: 218 citations2010: 215 citations2011: 290 citations2012: 256 citations2013: 237 citations2014: 247 citations2015: 239 citations2016: 222 citations2017: 200 citations2018: 188 citations2019: 588 citations2020: 682 citations2021: 818 citations2022: 653 citations2023: 503 citations2024: 696 citations2025: 351 citations2026: 17 citations1977–1978: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,879 citing papers, 27.5% of this breakdownUnited Kingdom: 1,033 citing papers, 7.3% of this breakdownChina: 739 citing papers, 5.2% of this breakdownItaly: 716 citing papers, 5.1% of this breakdownCanada: 655 citing papers, 4.6% of this breakdownNetherlands: 653 citing papers, 4.6% of this breakdownGermany: 643 citing papers, 4.6% of this breakdownAustralia: 557 citing papers, 4% of this breakdownJapan: 416 citing papers, 3% of this breakdownFrance: 388 citing papers, 2.8% of this breakdownSpain: 357 citing papers, 2.5% of this breakdownSwitzerland: 265 citing papers, 1.9% of this breakdown
0%27.5%Other 26.9%

Fields

  • Medicine78.5%
  • Biochemistry, Genetics and Molecular Biology11.8%
  • Immunology and Microbiology4.4%
  • Nursing0.9%
  • Computer Science0.7%
  • Neuroscience0.7%
  • Other3%

Topics

  • Lipoproteins and Cardiovascular Health9.4%
  • Diabetes, Cardiovascular Risks, and Lipoproteins6.3%
  • Cardiac Imaging and Diagnostics4.8%
  • Coronary Interventions and Diagnostics3.9%
  • Atherosclerosis and Cardiovascular Diseases3%
  • Acute Myocardial Infarction Research2.9%
  • Other69.7%

Coauthors

All papers

Open in search
  1. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 2,967

  2. Effects of Torcetrapib in Patients at High Risk for Coronary Events

    Authors: , , , , , , , , , , , , , , , - New England Journal of Medicine 2007 cited by 3,144

  3. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease

    Authors: , , , , , , , , , , - New England Journal of Medicine 2005 cited by 3,504

  4. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2020 cited by 313

  5. American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (ivus)31When citing this document, the American College of Cardiology would appreciate the following citation format: Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, Pinto FJ, Rosenfield K, Siegel RJ, Tuzcu EM, Yock PG. ACC Clinical Expert Consensus Document on Standards for the acquisition, measurement and reporting of intravascular ultrasound studies: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents (Committee to Develop a Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies [IVUS]). J Am Coll Cardiol2001;37:1478–92.33Address for reprints: This document is available on the ACC Website at www.acc.org. Reprints of this document are available for 5.00 each by calling 800-253-4636 (U.S. only) or writing to the Resource Center, American College of Cardiology, Educational Services, 9111 Old Georgetown Road, Bethesda, MD 20814-1699.

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2001 cited by 2,182

  6. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nita G. Forouhi, N. Charlotte Onland‐Moret, Yvonne T. van der Schouw, Renate B. Schnabel, Jaroslav A. Hubáček, Růžena Kubínová, Miglė Bacevičienė, Abdonas Tamošiūnas, Andrzej Pająk, Romanvan Topor-Madry, Urszula Stepaniak, Sofia Malyutina, Damiano Baldassarre, Bengt Sennblad, Elena Tremoli, Ulf dé Fairé, Fabrizio Veglia, Ian Ford, J. Wouter Jukema, Rudi G. J. Westendorp, Gert J. de Borst, Pim A. de Jong, Ale Algra, Wilko Spiering, Anke H. Maitland‐van der Zee, Olaf H. Klungel, Anthonius de Boer, Pieter A. Doevendans, Charles B. Eaton, Jennifer G. Robinson, David Duggan, John Kjekshus, John R. Downs, Antonio M. Gotto, Anthony Keech, Roberto Marchioli, Gianni Tognoni, Peter S. Sever, Neil R Poulter, David D. Waters, Terje R. Pedersen, Pierre Amarenco, Haruo Nakamura, John J.V. McMurray, James Lewsey, Daniel I. Chasman, Paul M. Ridker, Aldo P. Maggioni, Luigi Tavazzi, Kausik K. Ray, Sreenivasa Rao Kondapally Seshasai, JoAnn E. Manson, Jackie F. Price, Peter H. Whincup, Richard Morris, Debbie A. Lawlor, George Davey Smith, Yoav Ben‐Shlomo, Pamela J. Schreiner, Myriam Fornage, David S. Siscovick, Mary Cushman, Meena Kumari, Nick J Wareham, W. M. Monique Verschuren, Susan Redline, Sanjay R. Patel, John C. Whittaker, Anders Hamsten, Joseph A. Delaney and 33 more - The Lancet 2014 cited by 710

  7. Is There a Simple Way to Identify Insulin-Resistant Individuals at Increased Risk of Cardiovascular Disease?

    Authors: , , , , , , , - The American Journal of Cardiology 2005 cited by 667

  8. Body-Weight Fluctuations and Outcomes in Coronary Disease

    Authors: , , , , , - New England Journal of Medicine 2017 cited by 314

  9. HIV infection and coronary heart disease: mechanisms and management

    Authors: , - Nature Reviews Cardiology 2019 cited by 223

  10. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial

    Authors: , , , , , , , , - Circulation 2018 cited by 195

  11. Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2014 cited by 585

  12. Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy

    Authors: , , , , , , , , , , , , , - JAMA 2002 cited by 1,935

  13. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease

    Authors: , , , , , , , , , , - Neurology 2010 cited by 433

  14. Myocardial Infarction in the ISCHEMIA Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Circulation 2020 cited by 134

  15. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal - Quality of Care and Clinical Outcomes 2020 cited by 86

  16. Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)

    Authors: , , , , , , , , , , , , , , , , , , , , , - Diabetes Care 2024 cited by 53

  17. Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A 1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial

    Authors: , , , , , , - Circulation 2011 cited by 205

  18. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John R. Downs, John J.V. McMurray - European Heart Journal 2015 cited by 158

  19. Effects of Hormone Replacement Therapy and Antioxidant Vitamin Supplements on Coronary Atherosclerosis in Postmenopausal Women

    Authors: , , , , , , , , , , , , , , , - JAMA 2002 cited by 576

  20. Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease

    Authors: , , , , , , , , , , , , - The American Journal of Cardiology 2009 cited by 153

  21. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , J Van Het Hof‐Wiersma, P. P. Viergever, Frank L.J. Visseren, Robert N. Doughty, Robert C. Scott, Carlos Calvo, José Luis Díaz-Díaz, Francisco Fuentes, Blas Gil Extremera, Carlos Rilova Jericó, Laia Matas Pericas, Juan Díaz García, D. Eric Bolster, Michael J. Koren, Mahfouz El Shahawy, Gil Vardi, D. Weinstein, K. Zuzarte, Henry N. Ginsberg, Jennifer G. Robinson, Daniel J. Rader, Christopher P. Cannon, Helen M. Colhoun, John J.P. Kastelein, Yong Huo, Anders Olsson, David D. Waters, Dominique Larrey, Robert S. Rosenson, P. Patriarca, Geert Molenberghs, Pierluigi Tricoci, Kenneth W. Mahaffey, Renato D. Lópes, Bimal R. Shah, Rajendra H. Mehta, Matthew T. Roe, Zubin J. Eapen, Luciana Armaganijan, Adriana Bertolami, Sergio Leonardi, Brad J. Kolls, J. Dedrick Jordan, Grégory Ducrocq, Étienne Puymirat, Robin Mathews - Journal of the American Heart Association 2016 cited by 102

  22. Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes

    Authors: , , , , , , , , , , , - Diabetes Care 2006 cited by 528

  23. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gabriela Stamatescu, Jean‐Claude Grégoire, Lambert Busque, Christian Lavallée, Pierre‐Olivier Hétu, Jean‐Sébastien Paquette, Spyridon Deftereos, Sylvie Lévesque, Mariève Cossette, Anna Nozza, Malorie Chabot-Blanchet, Marie‐Pierre Dubé, Marie‐Claude Guertin, Guy Boivin - The Lancet Respiratory Medicine 2021 cited by 271

  24. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Didier Carrié, Jennifer Corbelli, Pierre Coste, Robbert de Winter, Abbey Diaz, S Eisenberg, Bruce W. Ennis, Jean Fajadet, Neil Fam, David Fortuin, C. Gessler, Cindy L. Grines, Diego de Sousa Guerra, H. Gum, Thomas Haldis, Ton Heestermans, Jean-Paul Herrman, T. Huynh, Elvin Kedhi, Michael J. Koren, Simon Kouz, Merrill Krolick, Gregory Kumkumian, Shahar Lavi, Ruijie Li, Arif Masud, Christopher McAlhany, Frank McGrew, Charles O’Shaughnessy, A. J. M. Oude Ophuis, Kirk Parr, William F. Penny, Yves Pesant, H. Post, Stuart Robinson, Josep Rodés‐Cabau, Andrew K. Roy, Sam Schulman, Fiona Spence, George A. Stouffer, Tomasz Styŝ, B. Sussex, Naeem Tahirkheli, Jean‐Claude Tardif, Jean Grégoire, Jurriën M. ten Berg, Ad J. van Boven, Clemens von Birgelen, Douglas Weinstein, Clemens von Birgelen, Douglas Weinstein - European Heart Journal 2014 cited by 252